Radiopharmaceuticals Market - Global Forecast 2026-2032

The Radiopharmaceuticals Market is projected to reach USD 6.20 Billion in 2026. It is expected to continue growing at a CAGR of 6.69%, reaching USD 9.19 Billion by 2032.

Radiopharmaceuticals are moving from a specialized nuclear medicine category into a high-value precision oncology and diagnostic imaging field. These radioactive compounds combine a biologically active targeting molecule with a medical radioisotope to visualize disease, characterize tumor biology, or deliver targeted radiation to diseased tissue while limiting exposure to surrounding healthy cells.

Market momentum is supported by the clinical adoption of PET and SPECT imaging, the expanding use of theranostics, and regulatory approvals for targeted radioligand therapies, including lutetium-177-based prostate-specific membrane antigen (PSMA) therapy. Demand is also tied to rising cancer prevalence, aging populations, and the need for earlier, more accurate diagnosis in oncology, cardiology, neurology, and endocrinology.

For industry vendors, the radiopharmaceuticals market is defined by scientific innovation and operational complexity. Short isotope half-lives, stringent radiation safety rules, GMP manufacturing requirements, and specialized logistics create high barriers to entry, while strong clinical utility and growing investment in radiopharmaceutical manufacturing capacity create durable opportunities.

Transformative Shifts in the Radiopharmaceuticals Landscape

The radiopharmaceuticals landscape is being reshaped by the convergence of molecular imaging, targeted radionuclide therapy, and personalized medicine. Diagnostics and therapeutics are increasingly linked through the theranostic model, where the same biological target can be used to identify eligible patients, quantify disease burden, and deliver precision radiation therapy.

A major shift is the transition from conventional imaging isotopes and broad-use nuclear medicine procedures toward highly specific oncology agents. Gallium-68, fluorine-18, technetium-99m, iodine-131, lutetium-177, radium-223, and emerging alpha emitters such as actinium-225 are central to product development strategies, each with distinct implications for production, distribution, radiation safety, and clinical workflow.

The competitive landscape is also changing as pharmaceutical developers, isotope producers, contract manufacturers, academic centers, and hospital radiopharmacies form integrated ecosystems. Securing radioisotope supply, validating decentralized or regional manufacturing models, and building physician confidence through evidence-based clinical outcomes are now decisive differentiators.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is adding cumulative value across the radiopharmaceutical lifecycle, from target discovery and ligand optimization to image reconstruction, lesion detection, dosimetry, and manufacturing quality control. AI-enabled imaging analytics can support more consistent PET and SPECT interpretation, reduce inter-reader variability, and help quantify treatment response using standardized parameters.

In radiopharmaceutical therapy, AI is especially relevant to patient-specific dosimetry. By integrating imaging data, organ segmentation, pharmacokinetic models, and clinical variables, AI tools can help estimate absorbed dose more efficiently and support safer, more individualized treatment planning. This is important as radioligand therapy moves beyond single fixed-dose approaches toward adaptive protocols.

AI also strengthens operational performance. Predictive models can improve isotope production planning, cold-chain and radiation-compliant logistics, batch release scheduling, and equipment maintenance. However, adoption depends on validated algorithms, explainable outputs, cybersecurity controls, and compliance with FDA, EMA, and other regulatory expectations for software used in clinical decision support and regulated manufacturing.

Key Regional Insights

North America remains one of the most advanced radiopharmaceutical regions due to broad PET and SPECT adoption, a large oncology care base, FDA-regulated product pathways, and expanding investment in lutetium-177 and actinium-225 supply chains. The United States is particularly influential because it combines academic nuclear medicine expertise, commercial radiopharmacy networks, and strong demand for prostate cancer imaging and therapy, while Canada contributes nuclear research capabilities and healthcare demand for oncology diagnostics.

Europe benefits from mature nuclear medicine infrastructure, EMA oversight, and strong clinical research networks across Germany, France, Italy, Spain, the United Kingdom, and Nordic countries. The region is advancing theranostics through university hospitals and cross-border clinical collaboration, while also addressing isotope security, radiation protection, and harmonization of radiopharmaceutical preparation standards.

Asia-Pacific is gaining strategic importance as China, Japan, India, South Korea, and Australia expand cancer diagnostics, cyclotron capacity, and radiopharmaceutical research. Japan has long-standing nuclear medicine capabilities, Australia has recognized isotope production strengths, China is scaling oncology infrastructure, and India is improving access through public and private nuclear medicine investments.

Latin America, led by Brazil and Mexico, presents growing demand for oncology and cardiology imaging but faces uneven access to PET infrastructure and specialized radiopharmacies. The Middle East, particularly GCC health systems, is investing in advanced oncology centers and nuclear medicine services, while Africa shows long-term potential as IAEA-supported capacity building improves training, equipment access, and regulatory readiness for safe radiopharmaceutical use.

Key Group Insights

ASEAN markets are progressing through investments in hospital-based nuclear medicine, PET/CT installation, and cancer care modernization. Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines vary significantly in infrastructure maturity, making regional partnerships, workforce training, and isotope logistics essential for improving radiopharmaceutical access across the bloc.

The GCC is becoming a high-investment cluster for advanced diagnostics and oncology treatment, supported by national health transformation programs in Saudi Arabia, the United Arab Emirates, Qatar, and neighboring states. Demand is supported by premium hospital development, medical tourism ambitions, and the need to localize complex specialty care, including PET imaging and targeted radionuclide therapy.

The European Union provides one of the most structured regulatory and research environments for radiopharmaceuticals. EU funding frameworks, cross-border clinical trials, and coordinated radiation protection standards support innovation, while the region continues to prioritize resilient isotope supply and GMP-compliant radiopharmacy practices.

BRICS countries represent a major development platform because Brazil, Russia, India, China, and South Africa combine large patient populations with expanding nuclear medicine needs and domestic healthcare modernization priorities. G7 markets continue to drive premium innovation, regulatory precedent, and commercialization of advanced radioligand therapies. NATO countries, many of which overlap with G7 and EU members, are also focused on nuclear security, isotope resilience, and protection of critical medical supply chains.

Key Country Insights

The United States leads commercialization of advanced radiopharmaceuticals through FDA approvals, clinical trial density, radiopharmacy networks, and rapid adoption of PSMA PET imaging and lutetium-177 therapies. Canada supports the market through nuclear research capabilities and healthcare demand for oncology imaging, while Mexico is expanding diagnostic access in major urban centers supported by growing private and public healthcare capacity.

Brazil is the largest Latin American opportunity due to its hospital base and oncology demand, although isotope distribution, reimbursement, and infrastructure concentration remain key constraints. The United Kingdom maintains strong academic and NHS-linked nuclear medicine capabilities, while Germany is a European leader in theranostics, radiochemistry, and clinical adoption. France benefits from advanced oncology research and radiopharmaceutical manufacturing expertise, and Italy and Spain continue to expand nuclear medicine access within public healthcare systems.

Russia has technical nuclear capabilities and domestic demand, though geopolitical constraints can affect collaboration and supply chains. China is rapidly scaling PET/CT access, oncology infrastructure, and domestic radiopharmaceutical development. India offers long-term growth through cancer burden, cost-sensitive care models, and expanding nuclear medicine capacity. Japan remains important for imaging innovation and an aging population, Australia contributes isotope production and research depth, and South Korea is advancing precision medicine through strong hospital systems and biotechnology investment.

Actionable Recommendations for Industry Leaders

Industry vendors should prioritize secure isotope access by diversifying reactor, cyclotron, generator, and accelerator-based supply options. A resilient sourcing strategy is essential because short half-lives, transport restrictions, and reactor maintenance schedules can directly affect patient treatment continuity.

Companies should invest in theranostic platforms that connect diagnostic imaging agents with matched therapeutic radiopharmaceuticals. This approach improves patient selection, strengthens clinical value propositions, and supports differentiated reimbursement discussions based on measurable outcomes.

Manufacturers and healthcare providers should expand GMP-compliant regional production, automated synthesis, digital batch documentation, and radiation-safe logistics. Vendors should also develop AI-enabled image quantification and dosimetry capabilities, but only through validated, auditable systems aligned with clinical and regulatory requirements.

Commercial success will depend on multidisciplinary education for oncologists, nuclear medicine physicians, radiologists, medical physicists, pharmacists, and payers. Building evidence around survival, quality of life, workflow efficiency, and total cost of care will be critical to accelerating adoption.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified public information from regulatory agencies, international health organizations, scientific literature, clinical trial registries, nuclear medicine authorities, and publicly available industry disclosures. Sources considered include FDA and EMA product information, IAEA nuclear medicine resources, WHO cancer burden references, peer-reviewed journals, and recognized radiation protection guidance.

The methodology emphasizes triangulation across clinical, regulatory, technological, and supply chain indicators. Key themes were evaluated by reviewing approved radiopharmaceutical products, isotope production routes, imaging and therapy adoption patterns, regional healthcare infrastructure, and the role of AI in nuclear medicine workflows.

Insights are presented qualitatively and avoid unsupported numerical claims. The analysis focuses on evidence-based market direction, operational constraints, regional differences, and strategic implications relevant to stakeholders across pharmaceutical development, isotope production, radiopharmacy, diagnostics, oncology care, and healthcare investment.

Conclusion

Radiopharmaceuticals are entering a defining phase as precision imaging and targeted radionuclide therapy become central to modern oncology and specialized diagnostics. The market is supported by clinical evidence, regulatory progress, expanding manufacturing investment, and growing demand for personalized treatment pathways.

The strongest opportunities will favor organizations that can combine scientific differentiation with operational reliability. Isotope security, GMP execution, AI-enabled workflow optimization, physician education, and payer evidence will determine which organizations convert innovation into scalable clinical adoption.

As healthcare systems seek earlier diagnosis and more targeted treatment, radiopharmaceuticals are positioned to become a critical pillar of precision medicine. Stakeholders that act now to build resilient platforms, compliant infrastructure, and outcome-driven partnerships will be best placed to lead the next stage of market development.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Radiopharmaceuticals Market, by Product Type

7.1. Introduction
7.2. Diagnostic
7.3. Therapeutic
7.4. Theranostic Pairs

8. Radiopharmaceuticals Market, by Product Format

8.1. Introduction
8.2. Ready-To-Use Products
8.3. Cold Kits
8.4. Radiolabeling Precursors

9. Radiopharmaceuticals Market, by Radioisotope Type

9.1. Introduction
9.2. Fluorine-18
9.3. Gallium-68
9.4. Iodine-131
9.5. Lutetium-177
9.6. Technetium-99m

10. Radiopharmaceuticals Market, by Production Technology

10.1. Introduction
10.2. Automated Synthesis Modules
10.3. Cyclotron Based
10.4. Generator Based
10.5. Reactor Based

11. Radiopharmaceuticals Market, by Molecule Type

11.1. Introduction
11.2. Small Molecules
11.3. Peptides
11.4. Monoclonal Antibodies
11.5. Particles And Microspheres

12. Radiopharmaceuticals Market, by Route Of Administration

12.1. Introduction
12.2. Intravenous
12.3. Oral
12.4. Intra-Arterial

13. Radiopharmaceuticals Market, by Dose Presentation

13.1. Introduction
13.2. Unit Dose
13.3. Multi-Dose

14. Radiopharmaceuticals Market, by Therapeutic Approach

14.1. Introduction
14.2. Radioligand Therapy
14.3. Radioimmunotherapy
14.4. Radioembolization
14.5. Bone-Targeted Therapy

15. Radiopharmaceuticals Market, by Application

15.1. Introduction
15.2. Cardiology
15.3. Endocrinology
15.4. Neurology
15.5. Oncology

16. Radiopharmaceuticals Market, by End User

16.1. Introduction
16.2. Clinics
16.3. Diagnostic Centres
16.4. Hospitals

17. Radiopharmaceuticals Market, by Region

17.1. Asia-Pacific
17.2. North America
17.3. Latin America
17.4. Europe
17.5. Middle East
17.6. Africa

18. Radiopharmaceuticals Market, by Group

18.1. ASEAN
18.2. GCC
18.3. European Union
18.4. BRICS
18.5. G7
18.6. NATO

19. Radiopharmaceuticals Market, by Country

19.1. United States
19.2. China
19.3. Germany
19.4. United Kingdom
19.5. India
19.6. Canada
19.7. Australia
19.8. Japan
19.9. France
19.10. Mexico
19.11. Brazil
19.12. Italy
19.13. Russia
19.14. South Korea
19.15. Spain

20. Competitive Landscape

20.1. Market Share Analysis, 2025
20.2. FPNV Positioning Matrix, 2025
20.3. Market Concentration Analysis, 2025
20.3.1. Concentration Ratio (CR)
20.3.2. Herfindahl Hirschman Index (HHI)
20.4. Recent Developments & Impact Analysis, 2025
20.5. Product Portfolio Analysis, 2025
20.6. Benchmarking Analysis, 2025

21. Company Profiles

21.1. 3B Pharmaceuticals GmbH
21.2. Abdera Therapeutics Inc.
21.3. Actineer Inc.
21.4. Actinium Pharmaceuticals, Inc.
21.5. Actithera Ltd.
21.6. AdvanCell Pty Ltd
21.7. Aktis Oncology, Inc.
21.8. Alliance Holdings Medical Limited
21.9. Alpha Tau Medical Ltd.
21.10. Alpha-9 Oncology Inc.
21.11. AmbioPharm, Inc.
21.12. ARTBIO, Inc.
21.13. Bayer AG
21.14. Bracco Group
21.15. BWX Technologies. Inc.
21.16. Cardinal Health, Inc.
21.17. Clarity Pharmaceuticals
21.18. Curium Pharma
21.19. Eckert & Ziegler Group
21.20. Eczacibasi-Monrol Nuclear Products Co.
21.21. GE HealthCare Technologies, Inc.
21.22. Global Medical Solutions
21.23. International Isotopes, Inc.
21.24. IsoTherapeutics Group, LLC
21.25. Isotopia Molecular Imaging Ltd.
21.26. Jubilant Pharma Holdings Inc.
21.27. Lantheus Medical Imaging, Inc.
21.28. Mallinckrodt PLC
21.29. Northstar Medical Technologies LLC
21.30. Novartis AG
21.31. NTP Radioisotopes SOC Ltd.
21.32. Siemens Healthineers AG
21.33. Sinotau Pharmaceutical Group

List of Figures

FIGURE 1. GLOBAL RADIOPHARMACEUTICALS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL RADIOPHARMACEUTICALS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL RADIOPHARMACEUTICALS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL RADIOPHARMACEUTICALS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2025 VS 2032 (%)
FIGURE 9. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 13. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025 VS 2032 (%)
FIGURE 21. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 25. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 29. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 31. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. GLOBAL RADIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 33. GLOBAL RADIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL RADIOPHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL DIAGNOSTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL DIAGNOSTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL THERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL THERAPEUTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL THERAPEUTIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL THERANOSTIC PAIRS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL THERANOSTIC PAIRS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL THERANOSTIC PAIRS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL READY-TO-USE PRODUCTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL READY-TO-USE PRODUCTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL READY-TO-USE PRODUCTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL COLD KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL COLD KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL COLD KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL RADIOLABELING PRECURSORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL RADIOLABELING PRECURSORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL RADIOLABELING PRECURSORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL FLUORINE-18 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL FLUORINE-18 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL FLUORINE-18 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL GALLIUM-68 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL GALLIUM-68 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL GALLIUM-68 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL IODINE-131 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL IODINE-131 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL IODINE-131 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL LUTETIUM-177 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL LUTETIUM-177 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL TECHNETIUM-99M MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL TECHNETIUM-99M MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL AUTOMATED SYNTHESIS MODULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL AUTOMATED SYNTHESIS MODULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL AUTOMATED SYNTHESIS MODULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL CYCLOTRON BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL CYCLOTRON BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL CYCLOTRON BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL GENERATOR BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL GENERATOR BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL GENERATOR BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL REACTOR BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL REACTOR BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL REACTOR BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL PEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PARTICLES AND MICROSPHERES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PARTICLES AND MICROSPHERES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PARTICLES AND MICROSPHERES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL INTRA-ARTERIAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL INTRA-ARTERIAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL INTRA-ARTERIAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL UNIT DOSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL UNIT DOSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL UNIT DOSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL MULTI-DOSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL MULTI-DOSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL MULTI-DOSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL RADIOLIGAND THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL RADIOLIGAND THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL RADIOLIGAND THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL RADIOIMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL RADIOIMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL RADIOIMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL RADIOEMBOLIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL RADIOEMBOLIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL RADIOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL BONE-TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL BONE-TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL BONE-TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL DIAGNOSTIC CENTRES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL DIAGNOSTIC CENTRES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL DIAGNOSTIC CENTRES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 130. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 141. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 142. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 143. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 144. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 146. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 152. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 153. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 154. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 155. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 156. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 157. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 158. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 159. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 160. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 161. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 162. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 164. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 165. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 166. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 167. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 168. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 169. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 170. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 174. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 175. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 176. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 177. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 178. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 179. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 180. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 181. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 182. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 183. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 184. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 185. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 186. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 187. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 188. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 189. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 190. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 191. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 192. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 193. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 194. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 195. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 196. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 197. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 198. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 199. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 200. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 201. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 202. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 203. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 204. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 205. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 206. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 207. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 219. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 220. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 221. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 222. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 223. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 224. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 225. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 226. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 227. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 228. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 229. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 230. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 231. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 232. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 233. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 234. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 235. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 236. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 237. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 238. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 239. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 240. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 242. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 243. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 244. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 245. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 246. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 247. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 248. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 249. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 250. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 251. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 252. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 253. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 254. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 255. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 256. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 257. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 258. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 259. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 260. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 261. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 262. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 263. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. CHINA RADIOPHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 265. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 266. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 267. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 268. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 269. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 270. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 271. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 272. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 273. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 274. CHINA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 275. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 276. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 277. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 278. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 279. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 280. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 281. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 282. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 283. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 284. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 285. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 289. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 290. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 291. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 292. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 293. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 294. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 295. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 296. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 297. INDIA RADIOPHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 298. INDIA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 299. INDIA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 300. INDIA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 301. INDIA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 302. INDIA RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 303. INDIA RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 304. INDIA RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 305. INDIA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 306. INDIA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 307. INDIA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 308. CANADA RADIOPHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 309. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 310. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 311. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 312. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 313. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 314. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 315. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 316. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 317. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 318. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 319. AUSTRALIA RADIOPHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 320. AUSTRALIA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 321. AUSTRALIA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 322. AUSTRALIA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 323. AUSTRALIA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 324. AUSTRALIA RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 325. AUSTRALIA RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 326. AUSTRALIA RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 327. AUSTRALIA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 328. AUSTRALIA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 329. AUSTRALIA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 330. JAPAN RADIOPHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 331. JAPAN RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 332. JAPAN RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 333. JAPAN RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 334. JAPAN RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 335. JAPAN RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 336. JAPAN RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 337. JAPAN RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 338. JAPAN RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 339. JAPAN RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 340. JAPAN RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 341. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 342. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 343. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 344. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 345. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 346. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 347. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 348. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2017-2032 (USD MILLION)
TABLE 349. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2017-2032 (USD MILLION)
TABLE 350. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 351. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 352. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 353. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 354. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2017-2032 (USD MILLION)
TABLE 355. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2017-2032 (USD MILLION)
TABLE 356. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 357. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 358. MEXICO RADIO

Companies Mentioned

3B Pharmaceuticals GmbH
Abdera Therapeutics Inc.
Actineer Inc.
Actinium Pharmaceuticals, Inc.
Actithera Ltd.
AdvanCell Pty Ltd
Aktis Oncology, Inc.
Alliance Holdings Medical Limited
Alpha Tau Medical Ltd.
Alpha-9 Oncology Inc.
AmbioPharm, Inc.
ARTBIO, Inc.
Bayer AG
Bracco Group
BWX Technologies. Inc.
Cardinal Health, Inc.
Clarity Pharmaceuticals
Curium Pharma
Eckert & Ziegler Group
Eczacibasi-Monrol Nuclear Products Co.
GE HealthCare Technologies, Inc.
Global Medical Solutions
International Isotopes, Inc.
IsoTherapeutics Group, LLC
Isotopia Molecular Imaging Ltd.
Jubilant Pharma Holdings Inc.
Lantheus Medical Imaging, Inc.
Mallinckrodt PLC
Northstar Medical Technologies LLC
Novartis AG
NTP Radioisotopes SOC Ltd.
Siemens Healthineers AG
Sinotau Pharmaceutical Group

Table Information

Report Attribute	Details
No. of Pages	181
Published	August 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 6.2 Billion
Forecasted Market Value ( USD ) by 2032	$ 9.19 Billion
Compound Annual Growth Rate	6.6%
Regions Covered	Global
No. of Companies Mentioned	33

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3168EUR$3,545USD£2,708GBP €3520EUR$3,939USD£3,009GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4793EUR$5,363USD£4,097GBP €5326EUR$5,959USD£4,552GBP

Transformative Shifts in the Radiopharmaceuticals Landscape

Cumulative Impact of Artificial Intelligence

Key Regional Insights

Key Group Insights

Key Country Insights

Actionable Recommendations for Industry Leaders

Research Methodology

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Radiopharmaceutical Therapy Market - Global Forecast 2026-2032

Nuclear Radiopharmaceutical Market - Global Forecast 2026-2032

Radiopharmaceuticals Market Report by Product Type, Application, End Use, and Region 2026-2034

Nuclear Medicine (Radiopharmaceuticals) - Market Insights, Competitive Landscape, and Market Forecast - 2034

Radiopharmaceuticals Third-Party Logistics Market Size, Share & Trends Analysis Report by Type, Service, Radioisotope Half-Life, Temperature Range, End Use, Region, and Growth Forecasts, 2026-2033